Researcher.Life Logo

BMC Medicine : Impact Factor & More

eISSN: 1741-7015pISSN: 1741-7015
JournalOpen Access

Aims and Scope of BMC Medicine

BMC Medicine is a peer-reviewed electronic-only medical journal published since 2003 by BioMed Central which is part of Springer Nature. It is described as "the flagship medical journal of the BMC series. An open access, open peer-reviewed general medical journal, BMC Medicine publishes outstanding and influential research in all areas of clinical practice, translational medicine, medical and health advances, public health, global health, policy, and general topics of interest to the biomedical and sociomedical professional communities". Less

Key Metrics

CiteScore
12.8
Eigenfactor
0.01 - 0.05
Impact Factor
5 - 10
Scite Index
0.87 5-Year SI
SJR
Q1Medicine (all)
SNIP
3.18
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on BMC Medicine

BMC Medicine Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher BMC
Language English
Frequency Continuous publication
Article Processing ChargesEUR 3090 | USD 3790 | GBP 2690
Publication Time10
Editorial Review ProcessOpen peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2003
Publisher URLVisit website
Website URLVisit website
Publication Details
Other chargesVisit website
PlagiarismVisit website
Publication Time 10
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessOpen peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC0
OA statementVisit website
View less

Planning to publish in BMC Medicine ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in BMC Medicine

Penpulimab in combination with lenalidomide and R-GemOx regimen (R2-GemOx-PD1i) in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm, phase 2 trial.
  • 9 Feb 2026
  • BMC medicine
Quantifying lifetime risk for 1,401 infectious diseases across the diabetes spectrum using a Bayesian approach.
  • 7 Feb 2026
  • BMC medicine
Risk assessment of asthma and allergic rhinitis in atopic dermatitis patients treated with biologics and JAK inhibitors: a systematic review and network meta-analysis of randomized controlled trials.
  • 7 Feb 2026
  • BMC medicine
Effects of ablation versus drug therapy on clinical outcomes and quality of life by frailty status in atrial fibrillation: a post hoc analysis of the CABANA trial.
  • 7 Feb 2026
  • BMC medicine
Preclinical activity of brincidofovir in peripheral T-cell and NK/T-cell lymphoma.
  • 6 Feb 2026
  • BMC medicine
Shared genetic architecture of psychoactive substance use and pan-cancer: insights from a large‑scale genome‑wide cross‑trait analysis.
  • 5 Feb 2026
  • BMC medicine
Penpulimab in combination with lenalidomide and R-GemOx regimen (R2-GemOx-PD1i) in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm, phase 2 trial.
  • 9 Feb 2026
  • BMC medicine
Quantifying lifetime risk for 1,401 infectious diseases across the diabetes spectrum using a Bayesian approach.
  • 7 Feb 2026
  • BMC medicine
Risk assessment of asthma and allergic rhinitis in atopic dermatitis patients treated with biologics and JAK inhibitors: a systematic review and network meta-analysis of randomized controlled trials.
  • 7 Feb 2026
  • BMC medicine
Effects of ablation versus drug therapy on clinical outcomes and quality of life by frailty status in atrial fibrillation: a post hoc analysis of the CABANA trial.
  • 7 Feb 2026
  • BMC medicine
Preclinical activity of brincidofovir in peripheral T-cell and NK/T-cell lymphoma.
  • 6 Feb 2026
  • BMC medicine
Shared genetic architecture of psychoactive substance use and pan-cancer: insights from a large‑scale genome‑wide cross‑trait analysis.
  • 5 Feb 2026
  • BMC medicine

FAQs on BMC Medicine